Health-related quality of life in cardiac sarcoidosis: A systematic review

Juan Carlos Quijano-Campos; Neha Sekhri; Muhunthan Thillai; Julie Sanders

doi:10.1093/ehjopen/oead009

Health-related quality of life in cardiac sarcoidosis: A systematic review

Juan Carlos Quijano-Campos^*, Neha Sekhri, Muhunthan Thillai, Julie Sanders

^*Corresponding author for this work

Digital Health & Applied Tech Assessment

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

People living with cardiac sarcoidosis (CS) are likely to have worse clinical outcomes and greater impairment on health-related quality of life (HRQoL) than other sarcoidosis manifestations. CS can result in a constellation of intrusive symptoms (such as palpitations, dizziness, syncope/pre-syncope, chest pain, dyspnoea, orthopnoea, or peripheral oedema) and/or life-Threatening episodes, requiring consideration of invasive cardiac procedures for diagnosis and for the management of acute events. Additionally, the presence of multisystemic involvement and persistent non-specific sarcoidosis symptoms negatively affect HRQoL. A systematic review was undertaken to explore the impact of CS on HRQoL in adults with CS. Multiple bibliographic databases were searched for studies with HRQoL as primary or secondary outcomes in CS (PROSPERO registration: CRD42019119752). Data extraction and quality assessments were undertaken independently by two authors. From the initial 1609 identified records, only 11 studies included CS patients but none specifically reported HRQoL scores for CS patients. The average representation of CS patients was 14.5% within these cohorts (range 2-22%). The majority (73%) was conducted in single-centre tertiary care settings, and only one study (9%) included longitudinal HRQoL data. CS patients were among those sarcoidosis patients with impaired HRQoL and worse outcomes, requiring higher doses of sarcoidosis-specific therapy which contribute to further deterioration of HRQoL. Sarcoidosis studies do not incorporate stratified HRQoL scores for CS patients. While there is a need for longitudinal and multicentre studies assessing HRQoL outcomes in CS cohorts, the development of CS-specific tools is also needed.

Original language	English
Article number	oead009
Journal	European heart journal open
Volume	3
Issue number	2
DOIs	https://doi.org/10.1093/ehjopen/oead009
Publication status	Published - 1 Mar 2023

Keywords

Cardiac sarcoidosis
Health-related quality of life (HRQoL)
Patient-reported outcome measures (PROMS)
Systematic review

Access to Document

10.1093/ehjopen/oead009

Cite this

@article{f7c3f2868e774e53bb823fc030816811,

title = "Health-related quality of life in cardiac sarcoidosis: A systematic review",

abstract = "People living with cardiac sarcoidosis (CS) are likely to have worse clinical outcomes and greater impairment on health-related quality of life (HRQoL) than other sarcoidosis manifestations. CS can result in a constellation of intrusive symptoms (such as palpitations, dizziness, syncope/pre-syncope, chest pain, dyspnoea, orthopnoea, or peripheral oedema) and/or life-Threatening episodes, requiring consideration of invasive cardiac procedures for diagnosis and for the management of acute events. Additionally, the presence of multisystemic involvement and persistent non-specific sarcoidosis symptoms negatively affect HRQoL. A systematic review was undertaken to explore the impact of CS on HRQoL in adults with CS. Multiple bibliographic databases were searched for studies with HRQoL as primary or secondary outcomes in CS (PROSPERO registration: CRD42019119752). Data extraction and quality assessments were undertaken independently by two authors. From the initial 1609 identified records, only 11 studies included CS patients but none specifically reported HRQoL scores for CS patients. The average representation of CS patients was 14.5% within these cohorts (range 2-22%). The majority (73%) was conducted in single-centre tertiary care settings, and only one study (9%) included longitudinal HRQoL data. CS patients were among those sarcoidosis patients with impaired HRQoL and worse outcomes, requiring higher doses of sarcoidosis-specific therapy which contribute to further deterioration of HRQoL. Sarcoidosis studies do not incorporate stratified HRQoL scores for CS patients. While there is a need for longitudinal and multicentre studies assessing HRQoL outcomes in CS cohorts, the development of CS-specific tools is also needed.",

keywords = "Cardiac sarcoidosis, Health-related quality of life (HRQoL), Patient-reported outcome measures (PROMS), Systematic review",

author = "Quijano-Campos, {Juan Carlos} and Neha Sekhri and Muhunthan Thillai and Julie Sanders",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology.",

year = "2023",

month = mar,

day = "1",

doi = "10.1093/ehjopen/oead009",

language = "English",

volume = "3",

journal = "European heart journal open",

issn = "2752-4191",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Health-related quality of life in cardiac sarcoidosis

T2 - A systematic review

AU - Quijano-Campos, Juan Carlos

AU - Sekhri, Neha

AU - Thillai, Muhunthan

AU - Sanders, Julie

PY - 2023/3/1

Y1 - 2023/3/1

N2 - People living with cardiac sarcoidosis (CS) are likely to have worse clinical outcomes and greater impairment on health-related quality of life (HRQoL) than other sarcoidosis manifestations. CS can result in a constellation of intrusive symptoms (such as palpitations, dizziness, syncope/pre-syncope, chest pain, dyspnoea, orthopnoea, or peripheral oedema) and/or life-Threatening episodes, requiring consideration of invasive cardiac procedures for diagnosis and for the management of acute events. Additionally, the presence of multisystemic involvement and persistent non-specific sarcoidosis symptoms negatively affect HRQoL. A systematic review was undertaken to explore the impact of CS on HRQoL in adults with CS. Multiple bibliographic databases were searched for studies with HRQoL as primary or secondary outcomes in CS (PROSPERO registration: CRD42019119752). Data extraction and quality assessments were undertaken independently by two authors. From the initial 1609 identified records, only 11 studies included CS patients but none specifically reported HRQoL scores for CS patients. The average representation of CS patients was 14.5% within these cohorts (range 2-22%). The majority (73%) was conducted in single-centre tertiary care settings, and only one study (9%) included longitudinal HRQoL data. CS patients were among those sarcoidosis patients with impaired HRQoL and worse outcomes, requiring higher doses of sarcoidosis-specific therapy which contribute to further deterioration of HRQoL. Sarcoidosis studies do not incorporate stratified HRQoL scores for CS patients. While there is a need for longitudinal and multicentre studies assessing HRQoL outcomes in CS cohorts, the development of CS-specific tools is also needed.

AB - People living with cardiac sarcoidosis (CS) are likely to have worse clinical outcomes and greater impairment on health-related quality of life (HRQoL) than other sarcoidosis manifestations. CS can result in a constellation of intrusive symptoms (such as palpitations, dizziness, syncope/pre-syncope, chest pain, dyspnoea, orthopnoea, or peripheral oedema) and/or life-Threatening episodes, requiring consideration of invasive cardiac procedures for diagnosis and for the management of acute events. Additionally, the presence of multisystemic involvement and persistent non-specific sarcoidosis symptoms negatively affect HRQoL. A systematic review was undertaken to explore the impact of CS on HRQoL in adults with CS. Multiple bibliographic databases were searched for studies with HRQoL as primary or secondary outcomes in CS (PROSPERO registration: CRD42019119752). Data extraction and quality assessments were undertaken independently by two authors. From the initial 1609 identified records, only 11 studies included CS patients but none specifically reported HRQoL scores for CS patients. The average representation of CS patients was 14.5% within these cohorts (range 2-22%). The majority (73%) was conducted in single-centre tertiary care settings, and only one study (9%) included longitudinal HRQoL data. CS patients were among those sarcoidosis patients with impaired HRQoL and worse outcomes, requiring higher doses of sarcoidosis-specific therapy which contribute to further deterioration of HRQoL. Sarcoidosis studies do not incorporate stratified HRQoL scores for CS patients. While there is a need for longitudinal and multicentre studies assessing HRQoL outcomes in CS cohorts, the development of CS-specific tools is also needed.

KW - Cardiac sarcoidosis

KW - Health-related quality of life (HRQoL)

KW - Patient-reported outcome measures (PROMS)

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85159698619&partnerID=8YFLogxK

U2 - 10.1093/ehjopen/oead009

DO - 10.1093/ehjopen/oead009

M3 - Review article

AN - SCOPUS:85159698619

SN - 2752-4191

VL - 3

JO - European heart journal open

JF - European heart journal open

IS - 2

M1 - oead009

ER -

Health-related quality of life in cardiac sarcoidosis: A systematic review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this